Searching for therapeutics against botulinum neurotoxins: A true challenge for drug discovery

Current Topics in Medicinal Chemistry

Volumn 16, Issue 21, 2016, Pages 2330-2349

  Duplantier, Allen J ^a,b,c   Kane, Christopher D ^b,c,d,e   Bavari, Sina ^c  

^a Geneva Foundation   (United States)

^b Division of Molecular and Translation Sciences   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Botulinum inhibitors; Botulinum neurotoxin; Botulism; Drug discovery; Protease inhibitors; SNAP 25

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; METALLOPROTEINASE; SNARE PROTEIN;

ARTICLE; BINDING AFFINITY; BOTULISM; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; EXOCYTOSIS; GENE TARGETING; HUMAN; LIGHT CHAIN; MUSCLE CONTRACTION; NEUROMUSCULAR JUNCTION; NEUROTRANSMISSION; PARALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT;

ANIMALS; BOTULINUM TOXINS; DRUG DISCOVERY; HUMANS;

EID: 84979017186     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160413135630     Document Type: Article

References (123)

1. Adalja, A.A.; Toner, E.; Inglesby, T.V. Clinical management of potential bioterrorism-related conditions. N. Engl. J. Med., 2015, 372 (10), 954-962.
2. Gill, D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev., 1982, 46 (1), 86-94.
3. Dembek, Z.F.; Smith, L.A.; Rusnak, J.M. In Medical Aspects of Biological Warfare. Z.F., D., Ed.; Office of the Surgeon General, US Army Medical Department Center and School, Borden Institute, Washington, D.C., 2007, pp 337-353.
4. Sobel, J. Botulism. Clin. Infect. Dis., 2005, 41 (8), 1167-1173.
5. Drag, M.; Salvesen, G.S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug. Discov., 2010, 9 (9), 690-701.
6. Flexner, C.; Bate, G.; Kirkpatrick, P. Tipranavir. Nat. Rev. Drug. Discov., 2005, 4 (12), 955-956.
7. Melnikova, I. The anticoagulants market. Nat. Rev. Drug. Discov., 2009, 8 (5), 353-354.
8. Smith, C.G.; Vane, J.R. The discovery of captopril. FASEB J., 2003, 17 (8), 788-789.
9. Turk, B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug. Discov., 2006, 5 (9), 785-799.
10. Hakami, R.M.; Ruthel, G.; Stahl, A.M.; Bavari, S. Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol., 2010, 18 (4), 164-172.
11. Kiris, E.; Burnett, J.C.; Kane, C.D.; Bavari, S. Recent advances in botulinum neurotoxin inhibitor development. Curr. Top. Med. Chem., 2014, 14 (18), 2044-2061.
12. BAT, Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) -(Equine) [Package Insert], Cangene Corporation. 2013.
13. Anniballi, F.; Lonati, D.; Fiore, A.; Auricchio, B.; De Medici, D.; Locatelli, C.A. New targets in the search for preventive and therapeutic agents for botulism. Expert Rev. Anti. Infect. Ther., 2014, 12(9), 1075-1086.
14. Al-Saleem, F.H.; Nasser, Z.; Olson, R.M.; Cao, L.; Simpson, L.L. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: a model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J. Pharmacol. Exp. Ther., 2011, 338 (2), 503-517.
15. Simpson, L. The life history of a botulinum toxin molecule. Toxicon, 2013, 68, 40-59.
16. Kane, C.D.; Nuss, J.E.; Bavari, S. Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 - 2014). Expert Opin. Ther. Pat., 2015, 25 (6), 675-690.
17. Adler, M.; Scovill, J.; Parker, G.; Lebeda, F.J.; Piotrowski, J.; Deshpande, S.S. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nervehemidiaphragm preparations. Toxicon, 1995, 33 (4), 527-537.
18. Harris, T.L.; Lowery, C.A.; Hixon, M.S.; Janda, K.D. A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity. ACS Chem. Neurosci., 2014, 5 (8), 632-636.
19. Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature, 2004, 432, 925-929.
20. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol., 1998, 5 (10), 898-902.
21. Segelke, B.; Knapp, M.; Kadkhodayan, S.; Balhorn, R.; Rupp, B. Crystal structure of Clostridium botulinum neurotoxin protease in a product-bound state: Evidence for noncanonical zinc protease activity. Proc. Natl. Acad. Sci. U. S. A., 2004, 101 (18), 6888-6893.
22. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol., 2000, 7 (8), 693-699.
23. Jin, R.; Sikorra, S.; Stegmann, C.M.; Pich, A.; Binz, T.; Brunger, A.T. Structural and biochemical studies of botulinum neurotoxin serotype C1 light chain protease: implications for dual substrate specificity. Biochemistry, 2007, 46 (37), 10685-10693.
24. Arndt, J.W.; Chai, Q.; Christian, T.; Stevens, R.C. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity. Biochemistry, 2006, 45 (10), 3255-3262.
25. Agarwal, R.; Eswaramoorthy, S.; Kumaran, D.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212-->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry, 2004, 43 (21), 6637-6644.
26. Agarwal, R.; Binz, T.; Swaminathan, S. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design. Biochemistry, 2005, 44 (35), 11758-11765.
27. Arndt, J.W.; Yu, W.; Bi, F.; Stevens, R.C. Crystal structure of botulinum neurotoxin type G light chain: serotype divergence in substrate recognition. Biochemistry, 2005, 44 (28), 9574-9580.
28. Hill, K.K.; Smith, T.J. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr. Top. Microbiol. Immunol., 2013, 364, 1-20.
29. Lebeda, F.J.; Cer, R.Z.; Mudunuri, U.; Stephens, R.; Singh, B.R.; Adler, M. The zinc-dependent protease activity of the botulinum neurotoxins. Toxins, 2010, 2 (5), 978-997.
30. Holmes, M.A.; Tronrud, D.E.; Matthews, B.W. Structural analysis of the inhibition of thermolysin by an active-site-directed irreversible inhibitor. Biochemistry, 1983, 22 (1), 236-240.
31. Swaminathan, S. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J., 2011, 278 (23), 4467-4485.
32. Brunger, A.T.; Rummel, A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon, 2009, 54 (5), 550-560.
33. Oost, T.; Sukonpan, C.; Brewer, M.; Goodnough, M.; Tepp, W.; Johnson, E.A.; Rich, D.H. Design and synthesis of substrate-based inhibitors of botulinum neurotoxin type B metalloprotease. Biopolymers, 2003, 71 (6), 602-619.
34. Zuniga, J.E.; Schmidt, J.J.; Fenn, T.; Burnett, J.C.; Arac, D.; Gussio, R.; Stafford, R.G.; Badie, S.S.; Bavari, S.; Brunger, A.T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure, 2008, 16 (10), 1588-1597.
35. Kumaran, D.; Rawat, R.; Ahmed, S.A.; Swaminathan, S. Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog., 2008, 4 (9), e1000165.
36. Botox [Package Insert], Allergan, Inc. 2013.
37. Dysport [Package Insert], Ipsen Biopharm Ltd. 2009.
38. Xeomin [Package Insert], Merz Pharmaceuticals, LLC. 2011.
39. Myobloc [Package Insert], Solstice Neurosciences, Inc. 2009.
40. Al-Saleem, F.H.; Ancharski, D.M.; Ravichandran, E.; Joshi, S.G.; Singh, A.K.; Gong, Y.; Simpson, L.L. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J. Pharmacol. Exp. Ther., 2008, 326 (3), 856-863.
41. Ravichandran, E.; Gong, Y.; Al Saleem, F.H.; Ancharski, D.M.; Joshi, S.G.; Simpson, L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther., 2006, 318 (3), 1343-1351.
42. Rummel, A.; Eichner, T.; Weil, T.; Karnath, T.; Gutcaits, A.; Mahrhold, S.; Sandhoff, K.; Proia, R.L.; Acharya, K.R.; Bigalke, H.; Binz, T. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. U. S. A., 2007, 104 (1), 359-364.
43. Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science, 2006, 312, 592-596.
44. Mahrhold, S.; Rummel, A.; Bigalke, H.; Davletov, B.; Binz, T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett., 2006, 580 (8), 2011-2014.
45. Dong, M.; Richards, D.A.; Goodnough, M.C.; Tepp, W.H.; Johnson, E.A.; Chapman, E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell. Biol., 2003, 162 (7), 1293-1303.
46. Nishiki, T.; Kamata, Y.; Nemoto, Y.; Omori, A.; Ito, T.; Takahashi, M.; Kozaki, S. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem., 1994, 269 (14), 10498-10503.
47. Rummel, A.; Karnath, T.; Henke, T.; Bigalke, H.; Binz, T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem., 2004, 279 (29), 30865-30870.
48. Montal, M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem., 2010, 79, 591-617.
49. Sun, S.; Suresh, S.; Liu, H.; Tepp, W.H.; Johnson, E.A.; Edwardson, J.M.; Chapman, E.R. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe, 2011, 10 (3), 237-247.
50. Sun, S.; Tepp, W.H.; Johnson, E.A.; Chapman, E.R. Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH. Biochemistry, 2012, 51 (28), 5655-5662.
51. Simpson, L.L.; Coffield, J.A.; Bakry, N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther., 1994, 269 (1), 256-262.
52. Koriazova, L.K.; Montal, M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol., 2003, 10 (1), 13-18.
53. Sanford, D.C.; Barnewall, R.E.; Vassar, M.L.; Niemuth, N.; Metcalfe, K.; House, R.V.; Henderson, I.; Shearer, J.D. Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1. Clin. Vaccine Immunol., 2010, 17(9), 1293-1304.
54. Eleopra, R.; Tugnoli, V.; Rossetto, O.; De Grandis, D.; Montecucco, C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett., 1998, 256 (3), 135-138.
55. Sloop, R.R.; Cole, B.A.; Escutin, R.O. Human response to botulinum toxin injection: type B compared with type A. Neurology, 1997, 49 (1), 189-194.
56. Foran, P.; Lawrence, G.W.; Shone, C.C.; Foster, K.A.; Dolly, J.O. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry, 1996, 35 (8), 2630-2636.
57. Tsai, Y.C.; Maditz, R.; Kuo, C.L.; Fishman, P.S.; Shoemaker, C.B.; Oyler, G.A.; Weissman, A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. U. S. A., 2010, 107 (38), 16554-16559.
58. Stahl, A.M.; Aldler, M.; Millard, C.B.; Gillfillan, L. Accelerating botulism therapeutic development in the department of defense. Drug Dev. Res., 2009, 70, 303-326.
59. Wilson, B.A.; Ho, M. Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism. Curr. Top. Med. Chem., 2014, 14 (18), 2081-2093.
60. Silvaggi, N.R.; Boldt, G.E.; Hixon, M.S.; Kennedy, J.P.; Tzipori, S.; Janda, K.D.; Allen, K.N. Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with smallmolecule inhibitors highlight active-site flexibility. Chem. Biol., 2007, 14 (5), 533-542.
61. Kiris, E.; Nuss, J.E.; Burnett, J.C.; Kota, K.P.; Koh, D.C.; Wanner, L.M.; Torres-Melendez, E.; Gussio, R.; Tessarollo, L.; Bavari, S. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res., 2011, 6 (3), 195-205.
62. Kiris, E.; Kota, K.P.; Burnett, J.C.; Soloveva, V.; Kane, C.D.; Bavari, S. Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert. Rev. Mol. Diagn., 2014, 14 (2), 153-168.
63. Pellett, S. Progress in cell based assays for botulinum neurotoxin detection. Curr. Top. Microbiol. Immunol., 2013, 364, 257-285.
64. Pellett, S.; Du, Z.W.; Pier, C.L.; Tepp, W.H.; Zhang, S.C.; Johnson, E.A. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem. Biophys. Res. Commun., 2011, 404 (1), 388-392.
65. Sheridan, R.E.; Deshpande, S.S.; Nicholson, J.D.; Adler, M. Structural features of aminoquinolines necessary for antagonist activity against botulinum neurotoxin. Toxicon, 1997, 35 (9), 1439-1451.
66. Schmidt, J.J.; Stafford, R.G.; Bostian, K.A. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite. FEBS Lett., 1998, 435 (1), 61-64.
67. Willis, B.; Eubanks, L.M.; Dickerson, T.J.; Janda, K.D. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew. Chem. Int. Ed., 2008, 47(44), 8360-8379.
68. Kumar, G.; Swaminathan, S. Recent developments with metalloprotease inhibitor class of drug candidates for botulinum neurotoxins. Curr. Top. Med. Chem., 2015, 15 (7), 685-695.
69. Li, B.; Peet, N.P.; Butler, M.M.; Burnett, J.C.; Moir, D.T.; Bowlin, T.L. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules, 2011, 16 (1), 202-220.
70. Dickerson, T.J.; Smith, G.R.; Pelletier, J.C.; Reitz, A.B. 8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A. Curr. Top. Med. Chem., 2014, 14 (18), 2094-2102.
71. Eubanks, L.M.; Hixon, M.S.; Jin, W.; Hong, S.; Clancy, C.M.; Tepp, W.H.; Baldwin, M.R.; Malizio, C.J.; Goodnough, M.C.; Barbieri, J.T.; Johnson, E.A.; Boger, D.L.; Dickerson, T.J.; Janda, K.D. An in vitro and in vivo disconnect uncovered through highthroughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. U. S. A., 2007, 104 (8), 2602-2607.
72. Thyagarajan, B.; Potian, J.G.; Garcia, C.C.; Hognason, K.; Capkova, K.; Moe, S.T.; Jacobson, A.R.; Janda, K.D.; McArdle, J.J. Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions. Neuropharmacology, 2010, 58 (8), 1189-1198.
73. Pang, Y.P.; Davis, J.; Wang, S.; Park, J.G.; Nambiar, M.P.; Schmidt, J.J.; Millard, C.B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PloS One, 2010, 5 (4), e10129.
74. Eichhorn, T.; Dolimbek, B.Z.; Deeg, K.; Efferth, T.; Atassi, M.Z. Inhibition in vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening. Toxicon, 2012, 60(6), 1180-1190.
75. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Disc. Today, 2004, 9 (10), 430-431.
76. Lipinski, C.A. Lead- and drug-like compounds: the rule-of-five revolution. Drug Disc. Today. Technol., 2004, 1 (4), 337-341.
77. Boldt, G.E.; Kennedy, J.P.; Janda, K.D. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org. Lett., 2006, 8 (8), 1729-1732.
78. Capek, P.; Zhang, Y.; Barlow, D.J.; Houseknecht, K.L.; Smith, G.R.; Dickerson, T.J. Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design. ACS Chem. Neurosci., 2011, 2 (6), 288-293.
79. Stowe, G.N.; Silhar, P.; Hixon, M.S.; Silvaggi, N.R.; Allen, K.N.; Moe, S.T.; Jacobson, A.R.; Barbieri, J.T.; Janda, K.D. Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. Org. Lett., 2010, 12 (4), 756-759.
80. Capkova, K.; Hixon, M.S.; McAllister, L.A.; Janda, K.D. Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem. Commun., 2008, 30, 3525-3527.
81. Schlimme, S.; Hauser, A.T.; Carafa, V.; Heinke, R.; Kannan, S.; Stolfa, D.A.; Cellamare, S.; Carotti, A.; Altucci, L.; Jung, M.; Sippl, W. Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem, 2011, 6 (7), 1193-1198.
82. Silhar, P.; Silvaggi, N.R.; Pellett, S.; Capkova, K.; Johnson, E.A.; Allen, K.N.; Janda, K.D. Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies. Bioorg. Med. Chem., 2013, 21 (5), 1344-1348.
83. Brunetto, A.T.; Ang, J.E.; Lal, R.; Olmos, D.; Molife, L.R.; Kristeleit, R.; Parker, A.; Casamayor, I.; Olaleye, M.; Mais, A.; Hauns, B.; Strobel, V.; Hentsch, B.; de Bono, J.S. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clinical Cancer Res., 2013, 19 (19), 5494-5504.
84. Jayaraman, R.; Pilla Reddy, V.; Pasha, M.K.; Wang, H.; Sangthongpitag, K.; Yeo, P.; Hu, C.Y.; Wu, X.; Xin, L.; Goh, E.; New, L.S.; Ethirajulu, K. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab. Dispos., 2011, 39 (12), 2219-2232.
85. Caglic, D.; Krutein, M.C.; Bompiani, K.M.; Barlow, D.J.; Benoni, G.; Pelletier, J.C.; Reitz, A.B.; Lairson, L.L.; Houseknecht, K.L.; Smith, G.R.; Dickerson, T.J. Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J. Med. Chem., 2014, 57 (3), 669-676.
86. Roxas-Duncan, V.; Enyedy, I.; Montgomery, V.A.; Eccard, V.S.; Carrington, M.A.; Lai, H.; Gul, N.; Yang, D.C.; Smith, L.A. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob. Agents and Chemother., 2009, 53 (8), 3478-3486.
87. Montgomery, V.A.; Ahmed, S.A.; Olson, M.A.; Mizanur, R.M.; Stafford, R.G.; Roxas-Duncan, V.I.; Smith, L.A. Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors. Toxicon., 2015, 98, 12-19.
88. Cardellina, J.H., 2nd; Vieira, R.C.; Eccard, V.; Skerry, J.; Montgomery, V.; Campbell, Y.; Roxas-Duncan, V.; Leister, W.; Leclair, C.A.; Maloney, D.J.; Padula, D.; Pescitelli, G.; Khavrutskii, I.; Hu, X.; Wallqvist, A.; Smith, L.A. Separation of Betti Reaction Product Enantiomers: Absolute Configuration and Inhibition of Botulinum Neurotoxin A. ACS Med. Chem. Lett., 2011, 2 (5), 396-401.
89. Singh, P.; Singh, M.K.; Chaudhary, D.; Chauhan, V.; Bharadwaj, P.; Pandey, A.; Upadhyay, N.; Dhaked, R.K. Retraction: Smallmolecule quinolinol inhibitor identified provides protection against BoNT/A in mice. PloS One, 2013, 8 (9). (DOI: 10.1371/annotation/049f74d0-919f-483c-a488-4740ec0a5f4d).
90. Schmidt, J.J.; Stafford, R.G. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett., 2002, 532 (3), 423-426.
91. Hale, M.; Oyler, G.; Swaminathan, S.; Ahmed, S.A. Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J. Biol. Chem., 2011, 286 (3), 1802-1811.
92. Blommaert, A.; Turcaud, S.; Anne, C.; Roques, B.P. Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity. Bioorg. Med. Chem., 2004, 12 (11), 3055-3062.
93. Solaja, B.A.; Opsenica, D.; Smith, K.S.; Milhous, W.K.; Terzic, N.; Opsenica, I.; Burnett, J.C.; Nuss, J.; Gussio, R.; Bavari, S. Novel 4- aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A. J. Med. Chem., 2008, 51 (15), 4388-4391.
94. Burnett, J.C.; Ruthel, G.; Stegmann, C.M.; Panchal, R.G.; Nguyen, T.L.; Hermone, A.R.; Stafford, R.G.; Lane, D.J.; Kenny, T.A.; McGrath, C.F.; Wipf, P.; Stahl, A.M.; Schmidt, J.J.; Gussio, R.; Brunger, A.T.; Bavari, S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem., 2007, 282(7), 5004-5014.
95. Opsenica, I.; Burnett, J.C.; Gussio, R.; Opsenica, D.; Todorovic, N.; Lanteri, C.A.; Sciotti, R.J.; Gettayacamin, M.; Basilico, N.; Taramelli, D.; Nuss, J.E.; Wanner, L.; Panchal, R.G.; Solaja, B.A.; Bavari, S. A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J. Med. Chem., 2011, 54 (5), 1157-1169.
96. Opsenica, I.; Filipovic, V.; Nuss, J.E.; Gomba, L.M.; Opsenica, D.; Burnett, J.C.; Gussio, R.; Solaja, B.A.; Bavari, S. The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar- range inhibition of the botulinum neurotoxin serotype A metalloprotease. Eur. J. Med. Chem., 2012, 53, 374-379.
97. Burnett, J.C.; Schmidt, J.J.; Stafford, R.G.; Panchal, R.G.; Nguyen, T.L.; Hermone, A.R.; Vennerstrom, J.L.; McGrath, C.F.; Lane, D.J.; Sausville, E.A.; Zaharevitz, D.W.; Gussio, R.; Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Comm., 2003, 310 (1), 84-93.
98. Ruthel, G.; Burnett, J.C.; Nuss, J.E.; Wanner, L.M.; Tressler, L.E.; Torres-Melendez, E.; Sandwick, S.J.; Retterer, C.J.; Bavari, S. Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. Toxins, 2011, 3 (3), 207-217.
99. Videnovic, M.; Opsenica, D.M.; Burnett, J.C.; Gomba, L.; Nuss, J.E.; Selakovic, Z.; Konstantinovic, J.; Krstic, M.; Segan, S.; Zlatovic, M.; Sciotti, R.J.; Bavari, S.; Solaja, B.A. Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria. J. Med. Chem., 2014, 57 (10), 4134-4153.
100. Cardellina, J.H., 2nd; Roxas-Duncan, V.I.; Montgomery, V.; Eccard, V.; Campbell, Y.; Hu, X.; Khavrutskii, I.; Tawa, G.J.; Wallqvist, A.; Gloer, J.B.; Phatak, N.L.; Holler, U.; Soman, A.G.; Joshi, B.K.; Hein, S.M.; Wicklow, D.T.; Smith, L.A. Fungal bis-Naphthopyrones as Inhibitors of Botulinum Neurotoxin Serotype A. ACS Me. Chem. Lett., 2012, 3 (5), 387-391.
101. Silhar, P.; Alakurtti, S.; Capkova, K.; Xiaochuan, F.; Shoemaker, C.B.; Yli-Kauhaluoma, J.; Janda, K.D. Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease. Bioorg. Med. Chem. Lett., 2011, 21 (8), 2229-2231.
102. Capkova, K.; Hixon, M.S.; Pellett, S.; Barbieri, J.T.; Johnson, E.A.; Janda, K.D. Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A’s zinc endopeptidase. Bioorg. Med. Chem. Lett., 2010, 20 (1), 206-208.
103. Li, B.; Cardinale, S.C.; Butler, M.M.; Pai, R.; Nuss, J.E.; Peet, N.P.; Bavari, S.; Bowlin, T.L. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Bioorg. Med. Chem., 2011, 19 (24), 7338-7348.
104. Bremer, P.T.; Hixon, M.S.; Janda, K.D. Benzoquinones as inhibitors of botulinum neurotoxin serotype A. Bioorg. Med. Chem., 2014, 22 (15), 3971-3981.
105. Eubanks, L.M.; Silhar, P.; Salzameda, N.T.; Zakhari, J.S.; Xiaochuan, F.; Barbieri, J.T.; Shoemaker, C.B.; Hixon, M.S.; Janda, K.D. Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. ACS Med. Chem. Lett., 2010, 1 (6), 268-272.
106. Silhar, P.; Capkova, K.; Salzameda, N.T.; Barbieri, J.T.; Hixon, M.S.; Janda, K.D. Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J. Am. Chem. Soc., 2010, 132(9), 2868-2869.
107. Salzameda, N.T.; Eubanks, L.M.; Zakhari, J.S.; Tsuchikama, K.; DeNunzio, N.J.; Allen, K.N.; Hixon, M.S.; Janda, K.D. A crossover inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action. Chem. Commun., 2011, 47 (6), 1713-1715.
108. Seki, H.; Xue, S.; Hixon, M.S.; Pellett, S.; Remes, M.; Johnson, E.A.; Janda, K.D. Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity. Chem. Commun., 2015, 51 (28), 6226-6229.
109. Beske, P.H.; Scheeler, S.M.; Adler, M.; McNutt, P.M., Accelerated intoxication of GABAergic synapses by botulinum neurotoxin A disinhibits stem cell-derived neuron networks prior to network silencing. Front Cell Neurosci., 2015, 9, 159.
110. Kiris, E.; Burnett, J.C.; Nuss, J.E.; Wanner, L.M.; Peyser, B.D.; Du, H.T.; Gomba, G.Y.; Kota, K.P.; Panchal, R.G.; Gussio, R.; Kane, C.D.; Tessarollo, L.; Bavari, S. SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. Neurotox Res., 2015, 27 (4), 384-398.
111. Kiris, E.; Nuss, J.E.; Stanford, S.M.; Wanner, L.M.; Cazares, L.; Maestre, M.F.; Du, H.T.; Gomba, G.Y.; Burnett, J.C.; Gussio, R.; Bottini, N.; Panchal, R.G.; Kane, C.D.; Tessarollo, L.; Bavari, S. Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays. PloS One, 2015, 10 (6), e0129264.
112. Goodman, A.D.; Stone, R.T. Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). Neurotherapeutics, 2013, 10 (1), 106-110.
113. Mizanur, R.M.; Frasca, V.; Swaminathan, S.; Bavari, S.; Webb, R.; Smith, L.A.; Ahmed, S.A. The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site. J. Biol. Chem., 2013, 288 (33), 24223-24233.
114. Mizanur, R.M.; Stafford, R.G.; Ahmed, S.A. Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin. PloS one, 2014, 9 (4), e95188.
115. Copeland, R.A. Mechanistic considerations in high-throughput screening. Anal. Biochem., 2003, 320 (1), 1-12.
116. Ouimet, T.; Duquesnoy, S.; Poras, H.; Fournie-Zaluski, M.C.; Roques, B.P. Comparison of fluorigenic peptide substrates PL50, SNAPTide, and BoTest A/E for BoNT/A detection and quantification: exosite binding confers high-assay sensitivity. J. Biomol. Screen., 2013, 18 (6), 726-735.
117. Ruge, D.R.; Dunning, F.M.; Piazza, T.M.; Molles, B.E.; Adler, M.; Zeytin, F.N.; Tucker, W.C. Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Anal. Biochem., 2011, 411(2), 200-209.
118. Smith, G.R.; Caglic, D.; Capek, P.; Zhang, Y.; Godbole, S.; Reitz, A.B.; Dickerson, T.J. Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the beta-exosite. Bioorg. Med. Chem. Lett., 2012, 22 (11), 3754-3757.
119. Tang, J.; Park, J.G.; Millard, C.B.; Schmidt, J.J.; Pang, Y.P. Computer- aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PloS one, 2007, 2 (8), e761.
120. Pang, Y.P.; Vummenthala, A.; Mishra, R.K.; Park, J.G.; Wang, S.; Davis, J.; Millard, C.B.; Schmidt, J.J. Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PloS one, 2009, 4 (11), e7730.
121. Ertl,P.; Rohde, B.; and Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties, J. Med. Chem., 2000, 43, 3714-3717.
122. Ghose, A. K.; Crippen, G. M. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structureactivity relationships. 2. Modeling dispersive and hydrophobic interactions, J. Chem. Inf. Comput. Sci., 1987, 27, 21-35.
123. Seki, H.; Xue, S.; Hixon, M. S.; Pellett, S.; Remes, M.; Johnson, E. A.; Janda, K. D. Toward the discovery of dual inhibitors for botulinum neurotoxin A: Concomitant targeting of endocytosis and light chain protease activity, Chem. Commun., 2015, 51, 6226-6229.